Several studies have shown the efficacy of RIT in patients with CD20+)B-cell NHL, both as a single agent in indolent lymphoma and in combination with chemotherapy in indolent and aggressive lymphoma [3, 5–9]. The gene discussed is MS4A1; the disease is B-cell non-Hodgkin lymphoma.